1
|
In-Silico Characterization of von Willebrand Factor Bound to FVIII. APPLIED SCIENCES-BASEL 2022. [DOI: 10.3390/app12157855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Factor VIII belongs to the coagulation cascade and is expressed as a long pre-protein (mature form, 2351 amino acids long). FVIII is deficient or defective in hemophilic A patients, who need to be treated with hemoderivatives or recombinant FVIII substitutes, i.e., biologic drugs. The interaction between FVIII and von Willebrand factor (VWF) influences the pharmacokinetics of FVIII medications. In vivo, full-length FVIII (FL-FVIII) is secreted in a plasma-inactive form, which includes the B domain, which is then proteolyzed by thrombin protease activity, leading to an inactive plasma intermediate. In this work, we analyzed through a computational approach the binding of VWF with two structure models of FVIII (secreted full-length with B domain, and B domain-deleted FVIII). We included in our analysis the atomic model of efanesoctocog alfa, a novel and investigational recombinant FVIII medication, in which the VWF is covalently linked to FVIII. We carried out a structural analysis of VWF/FVIII interfaces by means of protein–protein docking, PISA (Proteins, Interfaces, Structures and Assemblies), and protein contact networks (PCN) analyses. Accordingly, our computational approaches to previously published experimental data demonstrated that the domains A3-C1 of B domain-deleted FVIII (BDD-FVIII) is the preferential binding site for VWF. Overall, our computational approach applied to topological analysis of protein–protein interface can be aimed at the rational design of biologic drugs other than FVIII medications.
Collapse
|
3
|
Jun Z, Ming-Ming L, Qian-Qing Z, Yun-Hong W, Chong-Yang Z, Xin L. Functional identification of factor VIII B domain regions in hepatocyte cells. Biochem Biophys Res Commun 2020; 526:633-640. [PMID: 32248973 DOI: 10.1016/j.bbrc.2020.03.132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Accepted: 03/23/2020] [Indexed: 11/15/2022]
Abstract
Factor VIII (FVIII) functions as a cofactor within the intrinsic pathway of blood coagulation in process of FX activation by FIXa, for which deficiency results in the bleeding disorder hemophilia A. The gene of FVIII contains 26 exons that code for a 19 amino acid signal peptide and a 2332 amino acid polypeptide with a domain structure designated A1-A2-B-A3-C1-C2, of which the A domains are homologous with each other, as are the C domains. It has been well-documented that both the domains are the necessary elements for FVIII activities. The B domain is highly glycosylated and has a variable sequence, even among FVIIIs from different species. The B domain plays versatile roles in FVIII lifespan except for coagulation activity, but the functional characteristics of its specific regions remain still obscure. A series of recombinant FVIIIs (rFVIIIs) with B domain truncated were constructed and transiently expressed in hepatocyte cells. Media and cell lysates were collected after 72 h for the analyses of FVIII biosynthesis, secretion, activity and stability in ex vivo plasma relative to the full length wild-type FVIII. Unexpectedly, various regions in B domain exhibited different contribution to these functionalities. The discovery might facilitate the bioengineered rFVIIIs and gene therapeutics.
Collapse
Affiliation(s)
- Zhang Jun
- Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, 400016, China.
| | - Lin Ming-Ming
- Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, 400016, China
| | - Zhang Qian-Qing
- Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, 400016, China
| | - Wang Yun-Hong
- Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, 400016, China
| | - Zhu Chong-Yang
- Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, 400016, China
| | - Li Xin
- Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, 400016, China
| |
Collapse
|
4
|
Yazdani M, Chen X, Tashbayev B, Utheim ØA, Ræder S, Hua Y, Eidet JR, Stojanovic A, Dartt DA, Utheim TP. Evaluation of the Ocular Surface Disease Index Questionnaire as a Discriminative Test for Clinical Findings in Dry Eye Disease Patients. Curr Eye Res 2019; 44:941-947. [PMID: 30955380 DOI: 10.1080/02713683.2019.1604972] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Purpose: To investigate to what extent the OSDI can be utilized as a discriminative test for clinical findings. Methods: One thousand and ninety patients with dry eye disease (DED) were consecutively included and examined for osmolarity, tear film break-up time (TFBUT), ocular protection index (OPI), ocular surface staining (OSS), Schirmer I test (ST), meibum expressibility (ME), meibum quality (MQ), and diagnosis of meibomian gland dysfunction (MGD). Receiver-operating characteristic curve (ROC) analysis considering optimum balanced sensitivity and specificity (close to 50%) was used for assessment. Results: The present study on more than 1,000 patients indicates that the OSDI in the ROC curve analysis is a poor discriminator of pathological scores for TFBUT ≤ 5 (AUC = 0.553; p = .012) and ≤10 s (AUC = 0.608; p = .002), OSS ≥ 3 (AUC = 0.54; p = .043), ST ≤ 5 (AUC = 0.550; p = .032) and ≤10 mm/5 min (AUC = 0.544; p = .016), and ME ≥ 1 (AUC = 0.594; p = <0.001). Pathological scores for osmolarity >308 and >316 mOsm/L, OPI, OSS > 1, MQ, and MGD could not be discriminated by OSDI (p > .05). Conclusion: Cut-off values for the OSDI can be defined to discriminate pathological TFBUT (≤5 and ≤10), OSS (≥3), ST (≤5 and ≤10) and ME, however, the discriminability was low. Our comprehensive study emphasises the importance of taking both symptoms and signs into account in DED management.
Collapse
Affiliation(s)
- Mazyar Yazdani
- Department of Medical Biochemistry, Oslo University Hospital , Oslo , Norway.,The Norwegian Dry Eye Clinic , Oslo , Norway
| | - Xiangjun Chen
- The Norwegian Dry Eye Clinic , Oslo , Norway.,Department of Ophthalmology, Arendal Hospital , Arendal , Norway.,Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo , Oslo , Norway.,Faculty of Health Sciences, National Centre for Optics, Vision and Eye Care, University College of Southeast Norway , Kongsberg , Norway.,Department of Ophthalmology, Vestre Viken Hospital Trust , Drammen , Norway
| | - Behzod Tashbayev
- The Norwegian Dry Eye Clinic , Oslo , Norway.,Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo , Oslo , Norway
| | - Øygunn A Utheim
- Department of Medical Biochemistry, Oslo University Hospital , Oslo , Norway.,The Norwegian Dry Eye Clinic , Oslo , Norway
| | - Sten Ræder
- The Norwegian Dry Eye Clinic , Oslo , Norway
| | - Yanjun Hua
- Department of Ophthalmology, Shanghai Jiaotong University affiliated Sixth People's Hospital , Shanghai , China
| | - Jon R Eidet
- Department of Ophthalmology, Oslo University Hospital , Oslo , Norway
| | | | - Darlene A Dartt
- Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School , Boston , MA , USA
| | - Tor P Utheim
- Department of Medical Biochemistry, Oslo University Hospital , Oslo , Norway.,The Norwegian Dry Eye Clinic , Oslo , Norway.,Department of Ophthalmology, Arendal Hospital , Arendal , Norway.,Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo , Oslo , Norway.,Faculty of Health Sciences, National Centre for Optics, Vision and Eye Care, University College of Southeast Norway , Kongsberg , Norway.,Department of Ophthalmology, Vestre Viken Hospital Trust , Drammen , Norway.,Department of Plastic and Reconstructive Surgery, Oslo University Hospital , Oslo , Norway.,Department of maxillofacial surgery, Oslo University Hospital , Oslo , Norway.,Department of Ophthalmology, Stavanger University Hospital , Stavanger , Norway.,Department of Clinical Medicine, Faculty of Medicine, University of Bergen , Bergen , Norway
| |
Collapse
|